16/01/2026
Prof. Godfrey Grech, PhD, joins COMED Therapeutics’ Scientific Advisory Board, bringing expertise in molecular genetics, oncology, and clinical translation.
Academia Takes a Seat: COMED Therapeutics welcomes Prof. Godfrey Grech, PhD, to its Scientific Advisory Board.
With a career rooted in molecular genetics, oncology, and clinical translation, Prof. Grech brings a perspective shaped by both deep research and real-world application. His scientific insight will contribute meaningfully to how COMED evaluates, challenges, and advances its work in oncology, intracellular delivery, and precision biologics.
COMED Therapeutics has been named one of three finalists for Start-Up Business of the Year at the 2026 Malta Business Awards.
An independent study in CAPAN-2 pancreatic cancer cells found 68.7% more PI-positive objects following treatment with COMED Hooks versus matched nLNP controls.
An independent proteomic analysis of COMED’s pancreatic cancer program provides evidence of cell-state reprogramming following treatment with COMED Hooks.